Background Chimeric antigen receptor T cells are a promising new immunotherapy for
haematological malignancies. Six CAR-T cells products are currently available for adult …

In addition to conventional chemoradiation and targeted cancer therapy, the use of immune
based therapies, specifically immune checkpoint inhibitors (ICIs) and chimeric antigen …

Idecabtagene vicleucel (ide-cel) is a type of B-cell maturation antigen (BCMA)–targeting
chimeric antigen receptor T-cell (CAR-T) approved for the treatment of relapsed and …

Importance The frequency and clinical phenotypes of cardiotoxic events in chimeric antigen
receptor (CAR) T-cell recipients remain poorly understood given that landmark approval …

Malignant tumors of the hematologic system have a high degree of malignancy and high
mortality rates. Chimeric antigen receptor T cell (CAR-T) therapy has become an important …

Anthracycline-containing therapy is the cornerstone of frontline treatment for diffuse large B-
cell lymphoma (DLBCL), and autologous stem cell transplantation, and more recently …

Background Bispecific T-cell engagers (BTEs) are novel agents used to treat hematological
malignancies. Early trials were underpowered to define cardiovascular adverse events …

Abstract Aims Chimeric Antigen Receptor-T (CAR-T) cell infusion is a rapidly evolving
antitumor therapy; however, cardiovascular (CV) complications, likely associated with …

Chimeric antigen receptor T-cell (CAR-T) therapy has achieved durable response in patients
with hematological malignancies, however, therapy-associated multisystem toxicities are …

Background Cardiovascular events have been reported to occur in one in five patients
receiving chimeric antigen receptor T-cell (CAR-T) therapy. Commonly reported effects …